This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
ChemoCentryx 과거 수익 실적
과거 기준 확인 0/6
주요 정보
-47.2%
수익 성장률
-40.7%
EPS 성장률
Biotechs 산업 성장 | 17.0% |
매출 성장률 | -9.5% |
자기자본 수익률 | -56.3% |
순이익 | -357.0% |
최근 수익 업데이트 | 30 Jun 2022 |
최근 과거 실적 업데이트
Recent updates
ChemoCentryx shareholders approve $4.7B merger with Amgen
Oct 18ChemoCentryx GAAP EPS of -$0.44 misses by $0.03, revenue of $11.76M misses by $9.89M
Aug 09ChemoCentryx: Revisiting The Investment Case
Jun 21ChemoCentryx (NASDAQ:CCXI) Has Debt But No Earnings; Should You Worry?
Jun 06ChemoCentryx: Good Post-Approval Performance, But Needs More Time
Mar 03ChemoCentryx (NASDAQ:CCXI) Has Debt But No Earnings; Should You Worry?
Feb 11Analysts Are Betting On ChemoCentryx, Inc. (NASDAQ:CCXI) With A Big Upgrade This Week
Jan 21Checking In On ChemoCentryx
Dec 15Is ChemoCentryx (NASDAQ:CCXI) Using Debt In A Risky Way?
Oct 09ChemoCentryx: Make Or Break PDUFA Date For Avacopan May Not Go The Company's Way
Sep 29ChemoCentryx And Avacopan In ANCA-Associated Vasculitis: Making Amends
Aug 24Time To Worry? Analysts Just Downgraded Their ChemoCentryx, Inc. (NASDAQ:CCXI) Outlook
Aug 11ChemoCentryx: CRL Less Likely
Jul 25ChemoCentryx, Inc.'s (NASDAQ:CCXI) Intrinsic Value Is Potentially 34% Above Its Share Price
Jul 11ChemoCentryx (NASDAQ:CCXI) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Jun 15ChemoCentryx reports avacopan in ANCA vasculitis at ERA-EDTA congress
Jun 08ChemoCentryx: CRL Likely
May 09ChemoCentryx downgraded on narrow Adcom backing, Tilray jumps on double upgrade; in today’s analyst action
May 07Chemocentryx shares plunge 47% as FDA report identifies concerns with vasculitis candidate
May 04When Will ChemoCentryx, Inc. (NASDAQ:CCXI) Become Profitable?
Mar 03ChemoCentryx (NASDAQ:CCXI) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Feb 04ChemoCentryx: Great Drug, Good Prospects, Uncomfortable Stock Price
Jan 14Have ChemoCentryx, Inc. (NASDAQ:CCXI) Insiders Been Selling Their Stock?
Dec 31Analyst Forecasts Just Became More Bearish On ChemoCentryx, Inc. (NASDAQ:CCXI)
Dec 23ChemoCentryx's avacopan flunks mid-stage study in rare kidney disease study
Dec 21Did The Underlying Business Drive ChemoCentryx's (NASDAQ:CCXI) Lovely 934% Share Price Gain?
Dec 13Are Investors Undervaluing ChemoCentryx, Inc. (NASDAQ:CCXI) By 25%?
Nov 22ChemoCentryx, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 10수익 및 비용 분석
수익 및 비용 분석
ChemoCentryx 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
---|---|---|---|---|
30 Jun 22 | 37 | -133 | 97 | 0 |
31 Mar 22 | 27 | -141 | 89 | 0 |
31 Dec 21 | 32 | -132 | 79 | 0 |
30 Sep 21 | 34 | -121 | 68 | 0 |
30 Jun 21 | 22 | -123 | 59 | 0 |
31 Mar 21 | 69 | -63 | 50 | 0 |
31 Dec 20 | 65 | -55 | 42 | 0 |
30 Sep 20 | 71 | -41 | 36 | 0 |
30 Jun 20 | 76 | -30 | 32 | 0 |
31 Mar 20 | 34 | -65 | 27 | 0 |
31 Dec 19 | 36 | -55 | 24 | 0 |
30 Sep 19 | 35 | -51 | 23 | 0 |
30 Jun 19 | 34 | -49 | 22 | 0 |
31 Mar 19 | 42 | -40 | 21 | 0 |
31 Dec 18 | 43 | -38 | 20 | 0 |
30 Sep 18 | 90 | 12 | 19 | 0 |
30 Jun 18 | 90 | 17 | 17 | 0 |
31 Mar 18 | 84 | 14 | 17 | 0 |
31 Dec 17 | 82 | 18 | 17 | 0 |
30 Sep 17 | 31 | -29 | 16 | 0 |
30 Jun 17 | 26 | -30 | 16 | 0 |
31 Mar 17 | 20 | -31 | 15 | 0 |
31 Dec 16 | 12 | -40 | 15 | 0 |
30 Sep 16 | 7 | -44 | 15 | 0 |
30 Jun 16 | 3 | -48 | 15 | 0 |
31 Mar 16 | 0 | -51 | 15 | 0 |
양질의 수익: CCXI is currently unprofitable.
이익 마진 증가: CCXI is currently unprofitable.
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: CCXI is unprofitable, and losses have increased over the past 5 years at a rate of 47.2% per year.
성장 가속화: Unable to compare CCXI's earnings growth over the past year to its 5-year average as it is currently unprofitable
수익 대 산업: CCXI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (53%).
자기자본 수익률
높은 ROE: CCXI has a negative Return on Equity (-56.27%), as it is currently unprofitable.